Table 1.
Patient characteristics
| Total (n = 104) | P |
EGFR mutation with de novo MET amplification (n = 104) |
P | ||||
|---|---|---|---|---|---|---|---|
| EGFR-TKIa monotherapy (n = 48) | EGFR-TKI plus crizotinib (n = 9) | EGFR-TKI plus chemotherapy (n = 12) | Chemotherapy (n = 35) | ||||
| Age, median (range), years | 56 (27-84) | 56 (31-84) | 52 (27-66) | 56 (47-75) | 57 (44-73) | 0.728 | |
| Sex | 0.907 | 0.501 | |||||
| Male, n (%) | 52 (50.0) | 24 (50) | 6 (66.7) | 4 (33.3) | 18 (51.4) | ||
| Female, n (%) | 52 (50.0) | 24 (50) | 3 (33.3) | 8 (66.7) | 17 (48.6) | ||
| Smoking history | 0.723 | 0.544 | |||||
| Never smoker (no history of smoking), n (%) | 72 (69.2) | 16 (33.3) | 5 (55.6) | 2 (16.7) | 10 (28.6) | ||
| Former smoker (previous history of smoking), n (%) | 32 (30.8) | 32 (66.7) | 4 (44.4) | 10 (83.3) | 25 (71.4) | ||
| Histology | 0.894 | 0.758 | |||||
| Adenocarcinoma, n (%) | 103 (99.0) | 47 (97.9) | 9 (100.0) | 12 (100.0) | 35 (100.0) | ||
| Squamous cell carcinoma, n (%) | 1 (1.0) | 1 (2.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Stage | 0.204 | 0.511 | |||||
| Stage IIIb, n (%) | 12 (11.5) | 5 (10.4) | 1 (11.1) | 0 (0.0) | 6 (17.1) | ||
| Stage IV, n (%) | 92 (88.5) | 43(89.6) | 8 (88.9) | 12 (100.0) | 29 (82.9) | ||
| Brain metastasis at baseline | 0.280 | 0.479 | |||||
| Yes, n (%) | 31 (29.8) | 37 (77.1) | 7 (77.8) | 7 (58.3) | 23 (65.7) | ||
| No, n (%) | 73 (70.2) | 11 (22.9) | 2 (22.2) | 5 (41.7) | 12 (34.3) | ||
| EGFR mutation status | 0.006 | 0.420 | |||||
| Exon 19 deletion, n (%) | 65 (62.5) | 34 (70.8) | 6 (66.7) | 8 (66.7) | 17 (48.6) | ||
| Exon 21 L858R, n (%) | 26 (25.0) | 10 (20.8) | 1 (11.1) | 3 (25.0) | 12 (34.3) | ||
| Uncommon EGFR mutation, n (%) | 13 (12.5) | 4 (8.4) | 2 (22.2) | 1 (8.3) | 6 (17.1) | ||
EGFR, epidermal growth factor receptor; MET, mesenchymal–epithelial transition factor; TKI, tyrosine kinase inhibitor.
a
EGFR-TKI refers to gefitinib, erlotinib, afatinib, or osimertinib.